Edwards Lifesciences (EW) came out with quarterly earnings of $0.64 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.64 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this medical device maker would post earnings of $0.59 per share when it actually produced earnings of $0.59, delivering no surprise.Over the last four quarters, the company has surpassed consensus EPS estimates two times.Edwards Lifesciences, wh ...

Edwards Lifesciences (EW) recently secured the FDA’s approval for the EVOQUE tricuspid valve replacement system, a first-of-its-kind transcatheter therapy for the treatment of tricuspid regurgitation (TR). The system is indicated for the improvement of health status in patients with symptomatic severe TR despite optimal medical therapy (OMT), for whom tricuspid valve replacement is deemed appropriate by a heart team.The latest development will strongly boost the company’s Transcatheter Mitral and Tricuspid ...

Investors looking for stocks in the Medical - Instruments sector might want to consider either Integer (ITGR) or Edwards Lifesciences (EW) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, ...

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced the company’s EVOQUE tricuspid valve replacement system is the first transcatheter therapy to receive U.S. Food and Drug Administration (FDA) approval for the treatment of tricuspid regurgitation (TR). The EVOQUE system is indicated for the improvement of health status in patients with symptomatic severe TR despite optimal medical therapy (OMT), for whom tricuspid valve replacement is deemed appropriate by a heart t ...

In its upcoming report, Edwards Lifesciences (EW) is predicted by Wall Street analysts to post quarterly earnings of $0.64 per share, reflecting no change compared to the same period last year. Revenues are forecasted to be $1.5 billion, representing a year-over-year increase of 11.1%.Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.Prior to a company's ea ...

Edwards Lifesciences (EW) shares rallied 6.2% in the last trading session to close at $78.47. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 2.2% loss over the past four weeks.Edwards Lifesciences scored a strong price increase, on investors’ optimism surrounding its impending fiscal fourth-quarter 2023 financial results, which is slated to release on Feb 6 post the closing bell. Per the Zacks Consensus Esti ...

IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended December 31, 2023 after the market closes on Tuesday, February 6, 2024, and will host a conference call at 5:00 p.m. ET that day to discuss those results. To participate in the conference call, dial (877) 704-2848 or (201) 389-0893. The call will also be available live and archived on the “Investor Relations” section of the Edwards website at ir.edwards.com. About Edwards Lifescie ...

Investors interested in stocks from the Medical - Instruments sector have probably already heard of Integer (ITGR) and Edwards Lifesciences (EW) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision ...

Edwards Lifesciences Corporation (EW) is expected to report fourth-quarter and full-year 2023 results soon.In the last reported quarter, the company’s adjusted earnings per share of 59 cents matched the Zacks Consensus Estimate. The company’s earnings beat estimates in three of the trailing four quarters and were in line in the other. EW has a trailing four-quarter earnings surprise of 2.03% on average.Let's see how things have shaped up before this announcement.Factors at PlaySimilar to the last reported q ...

burcu onter/iStock via Getty ImagesInvestment Thesis Edwards Lifesciences Corporation (NYSE:EW) is down 3.10% over the last year but I am bullish on the stock given its optimistic outlook for 2024 and beyond which I find very realistic and backed with strong levers. The company has a clear growth strategy, which I am confident will lead to long-term sustainable growth. Based on comparative analysis, EW appears to have higher growth rates and profitability ratios than competitors; something I believe und ...